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   ABSTRACT 
  Objectives      To investigate the possible role of baseline 
plasma tumour necrosis factor alpha levels (baseline-TNF) 
on the clinical response to inﬂ  iximab in patients with 
rheumatoid arthritis (RA).   
  Methods      Patients with RA refractory to methotrexate 
received 3, 6, or 10 mg/kg of inﬂ  iximab every 8 weeks, 
in a randomised, double-blind manner: the RISING study. 
Clinical response (disease activity score in 28 joints 
based on C-reactive protein or American College of 
Rheumatology core set) at week 54 and serum inﬂ  iximab 
levels were compared in three patient groups with low, 
intermediate, or high baseline-TNF (TNF-low, TNF-int, or 
TNF-high).  
  Results      In TNF-low patients, the clinical response to 
different doses of inﬂ  iximab was comparable, whereas 
TNF-int patients exhibited a dose-dependent trend. 
In contrast, TNF-high patients (approximately 13% of 
the total patients) had a clinical response to 10 mg/kg 
signiﬁ  cantly better than the response to 3 and 6 mg/kg of 
inﬂ  iximab. In TNF-high patients, the median trough serum 
levels of inﬂ  iximab were below the detection limit (<0.1 
µg/ml) at 3 and 6 mg/kg but were greater than 2 µg/
ml at 10 mg/kg, whereas the levels were approximately 
1 µg/ml for each dosage group in TNF-low patients.   
  Conclusion      In patients with RA, baseline-TNF is 
signiﬁ  cantly associated with the clinical response to 
inﬂ  iximab in patients with a high baseline-TNF. A higher 
dose of inﬂ  iximab may be necessary in these patients, 
whereas lower doses of inﬂ  iximab are sufﬁ  cient for those 
with a low baseline-TNF. Baseline-TNF may be a useful 
measure for personalising the treatment of RA using 
inﬂ   iximab.      
  Rheumatoid arthritis (RA) is a chronic, systemic 
inﬂ  ammatory disease that results in joint destruc-
tion and disability.    1    Levels of tumour necrosis factor 
alpha (TNF), an inﬂ  ammatory cytokine, are elevated 
in the blood and synovial ﬂ  uid of patients with RA, 
and may play a central role in its pathogenesis.    2       –       7    
  Although inﬂ   iximab, an anti-TNF antibody, 
exhibits excellent effectiveness in RA,    8       –       11    insufﬁ  -
cient response to the standard treatment of inﬂ  ix-
imab (3 mg/kg per 8 weeks) has also been observed 
in some cases in clinical practice. Such patients are 
usually treated by dose escalation or by shortening 
the dose interval of the inﬂ  iximab therapy.    12       –       15    
  The RISING study (NCT00691028) is a ran-
domised, double-blind clinical trial, which has 
shown that the clinical response to inﬂ  iximab at a 
dose of 10 mg/kg is signiﬁ  cantly higher than the 
response to 3 mg/kg inﬂ  iximab, and that a trough 
serum level of 1 μg/ml is the threshold for clinical 
response.    16    However, clinical response to differ-
ent dose levels of inﬂ  iximab was signiﬁ  cant only 
for American College of Rheumatology (ACR) 
improvement criteria and the European League 
Against Rheumatism (EULAR) responses, and the 
measurable difference was small. 
  Several clinical studies have attempted to address 
whether a higher dose of inﬂ   iximab provides a 
better clinical response than standard doses in 
patients with RA.    8       –       11        17    However, the results were 
not consistent among those studies. In addition, a 
randomised, double-blind study comparing dose 
escalation and continuation of the standard dose in 
patients with RA who had an insufﬁ  cient response 
to 3 mg/kg of inﬂ  iximab clearly demonstrated no 
beneﬁ  cial response by dose escalation,    18    contrary 
to our results. 
  Although the standard dose of inﬂ  iximab can be 
efﬁ  cacious in a large proportion of patients with 
RA, some patients may require a higher dose of 
inﬂ   iximab to achieve clinical response.    19        20    The 
inconsistent results mentioned above might be 
explained by the different proportion of patients 
who might beneﬁ  t from inﬂ  iximab dose escalation 
in each study. Thus the clinical and immunological 
features of these patients who require higher dose 
of inﬂ  iximab are not fully understood.   
  It is tempting to speculate that the production 
and resultant plasma levels of TNF, the target mol-
ecule of inﬂ  iximab, exceeds the neutralising capac-
ity of inﬂ  iximab in insufﬁ  cient responders who are 
unable to maintain the threshold serum level of inf-
liximab. Considering that hypothesis, we analysed 
the RISING study data based on plasma TNF levels. 
We found that the clinical response of patients with 
high baseline levels of TNF (baseline-TNF) showed 
a signiﬁ  cant improvement with higher doses of inf-
liximab, whereas patients with low baseline-TNF 
did not have a better response even with higher 
doses of inﬂ  iximab. 
  METHODS 
    Patients and study protocol 
  The study protocol was approved by the local 
institutional review board and was carried out 
in accordance with the Helsinki Declaration and 
good clinical practice. Patient enrollment criteria 
and study design have previously been described 
in detail.    16    In the RISING study, 327 patients with 
active RA, despite receiving previous treatment 
with methotrexate, were administered 3 mg/kg 
inﬂ  iximab at weeks 0, 2 and 6 with methotrexate 
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less than 0.55 pg/ml, and a threefold higher level, 1.65 pg/ml, 
were adopted as cut-off values, and the patients were stratiﬁ  ed 
into the following three patient groups for analysis: low, less 
than 0.55 pg/ml (TNF-low); intermediate, 0.55 pg/ml or greater 
to less than 1.65 pg/ml (TNF-int); and high, 1.65 pg/ml or greater 
(TNF-high). 
  The association of baseline-TNF with baseline disease activ-
ity and the efﬁ  cacy of inﬂ  iximab therapy was analysed for the 
three groups described above (TNF-low, TNF-int and TNF-
high patients) employing the Kendall rank correlation coef-
ﬁ  cient. Baseline disease activity was analysed for the enrolled 
patients (n=327). Clinical responses (DAS28–CRP or ACR core 
set) and efﬁ  cacy on physical function (improved health assess-
ment questionnaire (HAQ) score) at week 54 were analysed 
using the last observation carried forward approach (n=307). 
Radiographic progression was analysed in the patients whose 
radiographic data were obtained at week 54 (n=273). The asso-
ciation between the serum inﬂ  iximab level and clinical response 
or disease activity at week 54 was analysed in the patients for 
whom both serum levels and DAS28–CRP values were obtained 
at week 54 (n=271). 
  Primary non-responders were deﬁ  ned as patients who had not 
achieved LDA throughout the study period (at weeks 2–54), and 
secondary non-responders as those who had not achieved LDA 
at week 54 but had achieved it at least once between weeks 2 
and 50. Kruskal–Wallis test analysis was performed to compare 
the rates of TNF-low, TNF-int and TNF-high patients in primary 
and secondary non-responders versus responders (those who 
had achieved LDA at week 54).     
  RESULTS 
    Patients’ background and association between baseline-TNF 
and parameters of disease activity at baseline 
    Table 1   shows the baseline demographics and clinical charac-
teristics of the enrolled patients (n=327). The median (IQR), 
minimum and maximum baseline-TNF values were 0.92 pg/ml 
(<0.55–1.29 pg/ml), less than 0.55 pg/ml and 9.68 pg/ml, respec-
tively. The proportion of patients with baseline-TNF values less 
than 0.55 pg/ml (undetectable), 0.55 pg/ml or greater to less than 
1.65 pg/ml, and 1.65 pg/ml or greater (TNF-low, TNF-int and 
TNF-high patients) was 28.7%, 58.4% and 12.8%, respectively. 
Details on the distribution of baseline-TNF can be found in sup-
plementary   ﬁ  gure 1   (available online only). Baseline-TNF was 
signiﬁ  cantly, but slightly, correlated with most parameters of 
disease activity and HAQ score, but not with radiographic pro-
gression (  table 2  ). The signiﬁ  cant correlations of baseline-TNF 
with RF and anti-CCP antibodies were also observed.         
    Clinical response to inﬂ  iximab at week 54 
  Of the enrolled patients, 307 were treated with 3, 6 or 10 mg/kg 
inﬂ  iximab during the blinded period, and clinical response was 
evaluated at week 54 using DAS28–CRP (  ﬁ  gure 1  ). The clinical 
responses at week 54 were signiﬁ  cantly higher in the 10 mg/kg 
group than in the 3 mg/kg group, and 45.2% of the patients in 
the 10 mg/kg group achieved DAS28–CRP remission.   
    Association between baseline-TNF and the efﬁ  cacy of 
inﬂ  iximab therapy at week 54 
  The EULAR responses and disease activities at week 54 in TNF-
low (n=87), TNF-int (n=180), and TNF-high (n=40) patients 
are shown in   ﬁ  gure 2A,B  . In TNF-low patients, the clinical 
response was similar among the 3, 6 and 10 mg/kg groups, 
showing no dose dependency. In TNF-int patients, the EULAR 
(open-label period weeks 0–14). Patients were randomly 
assigned into three groups using a dynamic allocation proce-
dure based on the clinical response at week 10 and were treated 
with 3 (n=99), 6 (n=104), or 10 (n=104) mg/kg inﬂ  iximab, every 
8 weeks from weeks 14 to 46, with methotrexate (blinded 
period weeks 14–54).   
    Laboratory test values and serum inﬂ  iximab measurement 
  Plasma samples for the evaluation of baseline-TNF were col-
lected just before the ﬁ  rst infusion of inﬂ  iximab (week 0). The 
plasma was separated from EDTA-supplemented blood and was 
stored at −20 to −80°C. Baseline-TNF levels were measured by 
ELISA using the QantiGlo ELISA Kit (QTA00B; R&D Systems 
Inc, Minneapolis, Minnesota, USA) in Mitsubishi Chemical 
Medience Corporation (Tokyo, Japan). Recombinant human TNF 
included in the kit was used as reference. Mitsubishi Chemical 
Medience Corporation has made minor modiﬁ  cations on the 
assay procedure of the ELISA kit (  http://www.rndsystems.com/
pdf/qta00b.pdf  ) and has validated their detection limit. Since the 
mean relative light units (2 SD) at blank and 0.55 pg/ml were 15.2 
(3.4) and 25.2 (5.0) by their modiﬁ  ed procedure, respectively, the 
detection limit was determined as 0.55 pg/ml by adding 2 SD 
to the relative light units. The coefﬁ  cient of variation or relative 
error values of intra-assay or inter-assay TNF were within 3.6% 
or 6.2%, respectively. They conﬁ  rmed that freezing and thawing 
the plasma sample 10 times and storing at −20°C for 22 weeks 
did not affect the stability of TNF in the plasma. 
  Sera were collected at weeks 0 and 2 and every 4 weeks 
thereafter. The serum inﬂ  iximab level was measured by ELISA 
using the anti-inﬂ  iximab monoclonal antibody obtained from 
Centocor Ortho Biotech Inc. (Horsham, Pennsylvania, USA).    8    
Serum inﬂ  iximab levels below 0.1 μg/ml were undetectable. 
  Baseline rheumatoid factor (RF) was measured by the latex 
agglutination test. Antibodies against cyclic citrullinated pep-
tides (CCP) and matrix metalloproteinase-3 (MMP-3) levels were 
measured by ELISA. The detectable ranges were as follows: RF, 
3 IU/ml or greater; anti-CCP antibodies, 0.6 IU/ml or greater to 
100 IU/ml or less; and MMP-3, 12.5 ng/ml or greater.   
  Evaluation  of  efﬁ  cacy 
  The clinical response to inﬂ  iximab was evaluated using EULAR 
criteria, and disease activity was assessed using the disease 
activity score in 28 joints (DAS28) based on C-reactive pro-
tein (CRP) and the ACR core set    21    at week 54. The EULAR 
response was evaluated using the DAS28 based on the erythro-
cyte sedimentation rate (ESR) assessment method (  http://www.
reuma-nijmegen.nl/www.das-score.nl/index.html  ). The cut-off 
values for DAS28–CRP were as follows, based on a report from 
Inoue   et al  .    22   : DAS28–CRP remission, less than 2.3; low disease 
activity (LDA), 2.3 or greater to less than 2.7; moderate disease 
activity (MDA), 2.7 or greater to 4.1 or less; high disease activity 
(HDA), greater than 4.1. Joint damage was assessed by the total 
modiﬁ  ed Sharp score (0–390 points).    23      
  Analytical  method 
  The clinical responses to inﬂ  iximab at week 54 were analysed 
for the full analysis set using the last observation carried forward 
approach. For the comparison of clinical response among dose 
groups (3, 6 and 10 mg/kg), logistic regression analysis was per-
formed using the clinical responses at the time of randomisation 
(week 10) as a covariate. 
  Because there is no well-established threshold value for an 
abnormal TNF level in the ELISA kit used, the detection limit, 
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On the other hand, those of primary non-responders (n=88) 
were 21.6%, 62.5% and 15.9%, and those of secondary non-
responders (n=71) were 23.9%, 57.7% and 18.3%, respectively. 
Signiﬁ   cant differences were observed between the respond-
ers and both of the non-responders (p=0.016 and p=0.032, 
respectively).   
    Association between baseline-TNF and serum inﬂ  iximab level 
  Clinical response to inﬂ  iximab has been shown to be inﬂ  u-
enced by trough serum inﬂ   iximab levels, and the threshold 
level for clinical response is approximately 1 μg/ml.    20        24    In this 
study, the median (IQR) serum inﬂ  iximab level at week 54 in 
patients with EULAR good response, moderate response and 
no response was 3.1 (1.2–7.1), 1.2 (<0.1–3.6) and less than 0.1 
(<0.1–0.4) μg/ml. The median (IQR) level in patients in DAS28–
CRP remission, with LDA, with MDA and with HDA at week 
54 was 3.4 (1.5–7.5), 2.1 (0.4–4.7), 1.4 (<0.1–4.0) and less than 
0.1 (<0.1–0.7) μg/ml, respectively. A signiﬁ  cant association was 
observed between clinical response or disease activity and the 
serum inﬂ  iximab level (both p<0.001). In patients with high 
trough serum inﬂ  iximab levels, better clinical responses were 
attained. Meanwhile, in patients with poor clinical response 
(EULAR no response, high disease activity), the median trough 
serum level was undetectable (<0.1 μg/ml). 
  Baseline-TNF greatly affected the serum inﬂ  iximab levels (  ﬁ  g-
ure 3A–C  ). In TNF-low patients, the median trough serum inf-
liximab levels were equivalent to or greater than the threshold 
level (1 μg/ml) in all groups (3, 6 and 10 mg/kg). For TNF-int 
patients, the 3 mg/kg dose did not achieve the threshold level 
of inﬂ  iximab but did provide a detectable level (≥0.1 μg/ml). 
However, in TNF-high patients, the median trough serum inﬂ  ix-
imab levels were undetectable at both 3 and 6 mg/kg doses, in 
contrast to the 10 mg/kg dose, at which a high level (>2 μg/ml) 
was maintained.   
  The positive rates for anti-inﬂ  iximab antibodies (human anti-
chimeric antibodies; HACA), which is reported to inﬂ  uence the 
serum inﬂ  iximab level    25    were 27.3%, 23.1% and 12.5% in the 3, 
6 and 10 mg/kg dose levels, respectively. In patients who were 
negative for HACA, the serum inﬂ  iximab level was also lower 
in TNF-high patients than in TNF-low patients, and the median 
serum inﬂ  iximab levels at the 3 mg/kg dose at week 54 in TNF-
low patients (n=23), TNF-int patients (n=37) and TNF-high 
patients (n=8) were 1.0, 0.6 and 0.2 μg/ml, respectively.   
    Association between safety and baseline-TNF or serum 
inﬂ  iximab level 
  The incidences of adverse events (total, serious events, infection, 
serious infection, or infusion reaction) were almost comparable 
among patients receiving 3, 6 and 10 mg/kg doses in TNF-low, 
TNF-int and TNF-high patients. We could ﬁ  nd no clear associa-
tion between the incidence of adverse events and the trough 
serum level of inﬂ  iximab either (supplementary table 3, avail-
able online only).     
  DISCUSSION 
  Although dose escalation or shortening of the administration 
interval between administrations has been used for patients with 
RA who show an insufﬁ  cient response to the standard dose of 
inﬂ  iximab (3 mg/kg for 8 weeks after initial induction), the effec-
tiveness of these countermeasures is still controversial.    18       –       20        26       –       32    
In this report, we hypothesised that the production and resultant 
plasma level of TNF exceeds the neutralising capacity of inﬂ  ix-
imab in insufﬁ  cient responders; and that inﬂ  iximab is consumed 
  Table  1         Baseline demographics and clinical characteristics of patients 
enrolled in the RISING study (n=327)   
   Baseline  value 
Age, year 49.9 (12.0)
Gender, female 267 (81.7)*
Disease duration, years 8.2 (8.0)
Steinbrocker stage
 I 32  (9.8)*
 II 114  (34.9)*
 III 105  (32.1)*
 IV 76  (23.2)*
Steinbrocker functional class
   1 58  (17.7)*
   2 239  (73.1)*
   3 30  (9.2)*
   4 0  (0.0)*
Duration of methotrexate use, years 2.7 (2.8)
Methotrexate dose, mg/week 7.8 (1.7)
Glucocorticoid use 223 (68.2)*
DAS28–CRP 5.5 (4.9, 6.2)†
DAS28–ESR
TJC, 68 joints
6.2 (5.6, 6.8)†
15.0 (10.0, 23.0)†
SJC, 66 joints 12.0 (9.0, 17.0)†
CRP, mg/dl 2.4 (1.2, 4.1)†
ESR, mm/h 52 (35, 72)†
Patient pain VAS, mm 54 (39, 72)†
Patient global VAS, mm 54 (36, 72)†
Physician global VAS, mm 64 (50, 78)†
TSS‡ 35.5 (11.5, 73.4)†
Estimated yearly progression of TSS, point/year‡ 6.1 (3.1, 11.4)†
HAQ 1.1 (0.8, 1.6)†
RF value, IU/ml 90 (36, 223)†
Anti-CCP antibodies value, IU/ml ≥100 (28, ≥100)†
MMP-3 value, ng/ml 219 (105, 419)†
      Data in baseline values are mean (SD), *number of patients (%), or †median (IQR). 
  Health assessment questionnaire (HAQ) score: scores can range from 0 (no difﬁ  culty) to 
3 (unable to perform this activity). 
  Total modiﬁ  ed Sharp score (TSS): scores can range from 0 to 390 (erosion score 0–230, 
joint space narrowing score 0–160), with high scores indicating more joint damage. 
Estimated yearly rate of progression of the TSS was based on the duration of disease 
and baseline TSS for every patient. 
  ‡n=325. 
  CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS 28, disease activity score 
in 28 joints; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; 
RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual 
analogue  scale.   
response rate increased and disease activity decreased as the 
dose increased, but without signiﬁ  cant difference. For TNF-
high patients, the clinical response and disease activity were 
signiﬁ  cantly better at 10 mg/kg than at 3 mg/kg and 6 mg/kg. 
The good response rates were 14%, 31% and 60% in the 3, 6 
and 10 mg/kg groups, respectively, and the DAS28–CRP remis-
sion rates were 7%, 31% and 50%, respectively. A similar 
inﬂ  uence by baseline-TNF was also noted on the ACR core set 
(  ﬁ  gure 2C  ). Signiﬁ  cant dose dependency was observed only in 
TNF-high patients.   
  Baseline-TNF at clinical response is shown in supplemen-
tary table 1 (available online only). Clinical response was sig-
niﬁ  cantly inﬂ  uenced by baseline-TNF in the 3 mg/kg group, but 
not in the 6 and 10 mg/kg groups. Baseline-TNF also inﬂ  uenced 
the improving physical function, in which the improvement in 
the HAQ score values and the rates of patients with meaning-
ful improvement (>0.22) in all dosage groups were signiﬁ  cantly 
different in TNF-high patients (supplementary table 2, available 
online only). Meanwhile, none of the groups showed signiﬁ  cant 
association with radiographic progression. 
  The proportions of TNF-low, TNF-int and TNF-high patients in 
responders (n=148) were 34.5%, 56.8% and 8.8%, respectively. 
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this association was not reﬂ  ected by the presence of HACA 
status. 
  It has been suggested that the threshold serum level for inﬂ  ix-
imab efﬁ  cacy on radiographic progression might be lower than 
that for clinical response.    33    In this study, approximately 90% of 
the patients whose serum level could be maintained over the 
threshold for radiographic progression, including even TNF-high 
patients, showed no radiographic progression. It may explain 
why baseline-TNF status had no inﬂ  uence on radiographic pro-
gression as observed in this study. 
  The present report has demonstrated that higher doses of 
inﬂ  iximab exhibited signiﬁ  cantly better clinical and functional 
response in patients with high baseline-TNF, whereas clini-
cal and functional response was comparable among patients 
administered 3, 6 and 10 mg/kg of inﬂ   iximab with low 
baseline-TNF. 
  We had reported previously that there was no difference in 
the safety proﬁ  le among groups receiving 3, 6 or 10 mg/kg.    16    
The rates of adverse events were almost comparable among 
all dosage groups in TNF-low, TNF-int and TNF-high patients. 
However, it has been reported that high-dose inﬂ  iximab therapy 
might increase the risk of adverse events.    11        34        35    So, the balance 
between risk and beneﬁ  t should be considered at the time of 
inﬂ  iximab dose escalation, even in TNF-high patients. 
  There have been several reports on the association between 
TNF level and the efﬁ  cacy of inﬂ  iximab.    36       –       39    Although the rea-
son for the inconsistent results is unclear, the serum TNF level 
was measured by bioassay in the report by Marotte  et al  ,    37    which 
is different from this study, in which ELISA was employed. In 
the studies by Wijbrandts   et al  ,    38    clinical response was evalu-
ated at week 16, 2 weeks after inﬂ  iximab administration when a 
high serum inﬂ  iximab level may have been maintained even in 
patients with a high baseline-TNF. These differences may have 
led to the different conclusions. 
  In the RISING study, baseline-TNF was measured in one 
institution (Mitsubishi Chemical Medience Corporation) con-
currently, where minor modiﬁ  cations were made in the original 
assay procedure and validated for the commercial use of clinical 
samples. 
to neutralise the TNF, decreasing the serum inﬂ  iximab level in 
those patients. 
  In our study, clinical responses at doses of 3, 6 and 10 mg/kg 
of inﬂ  iximab were comparable in TNF-low patients, and the 
minimum serum inﬂ  iximab level required for clinical response 
(approximately 1 μg/ml) was maintained, even in the 3 mg/
kg group. Accordingly, the maximal clinical responses can be 
achieved even with 3 mg/kg therapy in TNF-low patients. In 
other words, dose escalation does not provide any beneﬁ  t 
in this population. In contrast, in TNF-high patients, clinical 
responses at 3 and 6 mg/kg were signiﬁ  cantly decreased in 
comparison with the response to a 10 mg/kg dose. The trough 
serum inﬂ  iximab levels were ‘undetectable’ at 3 and 6 mg/
kg but were greater than 2 μg/ml with a 10 mg/kg dose. As 
the association between baseline-TNF and the serum inﬂ  ix-
imab level was also observed in HACA-negative patients, 
  Table  2         Baseline disease activities in TNF-low, TNF-int and TNF-high patients   
 
 Baseline-TNF 
  p Value (overall)   TNF-low  (n=94)   TNF-int  (n=191)   TNF-high  (n=42) 
DAS28-CRP 5.3 (4.9, 5.9) 5.5 (5.0, 6.2) 5.9 (5.2, 6.7) 0.002
DAS28-ESR 5.9 (5.5, 6.4) 6.2 (5.7, 6.8) 6.8 (6.2, 7.3) <0.001
TJC, 68 joints 14.0 (10.0, 21.0) 15.0 (11.0, 23.0) 16.5 (12.0, 23.0) 0.153
SJC, 66 joints 11.0 (8.0, 16.0) 13.0 (9.0, 17.0) 12.5 (10.0, 18.0) 0.041
Patient pain VAS, mm 49.0 (37.0, 65.0) 58.0 (40.0, 72.0) 68.5 (46.0, 88.0) <0.001
Patient global VAS, mm 51.0 (36.0, 64.0) 56.0 (36.0, 72.0) 65.0 (43.0, 86.0) 0.016
Physician global VAS, mm 62.0 (50.0, 75.0) 65.0 (49.0, 77.0) 72.0 (51.0, 82.0) 0.081
CRP (mg/dl) 2.0 (1.0, 3.9) 2.4 (1.2, 3.9) 2.8 (1.4, 5.8) 0.028
ESR (mm/h) 46.0 (33.0, 65.0) 53.0 (35.0, 72.0) 67.5 (40.0, 89.0) 0.001
HAQ 1.0 (0.5, 1.4) 1.1 (0.9, 1.6) 1.4 (1.0, 2.1) 0.002
TSS 37.0 (10.5, 76.0)* 36.0 (12.5, 72.3)† 22.5 (13.0, 56.0) 0.960
Estimated yearly progression of TSS, point/year 5.8 (2.8, 12.0)* 6.3 (3.4, 11.3)† 5.5 (2.5, 10.0) 0.833
RF value, IU/ml   85 (27, 215)     81 (37, 167)   238 (126, 554) 0.007
Anti-CCP antibodies value, IU/ml   91 (17, ≥100) ≥100 (30, ≥100) ≥100 (≥100, ≥100) 0.012
MMP-3 value, ng/ml 205 (105, 377)   216 (102, 391)   268 (114, 640) 0.214
      Data in baseline value are median (IQR). 
  Baseline disease activities were evaluated in the patients enrolled in the RISING study (n=327). The associations of baseline-tumour necrosis factor alpha (TNF) with baseline disease 
activities were analysed in the three groups (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coefﬁ  cient. 
 *n=93. 
  †n=190. 
  CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; 
MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TSS, total modiﬁ  ed Sharp score; VAS, visual analogue scale.     
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 Figure  1        Clinical responses to inﬂ  iximab therapy in patients with 
rheumatoid arthritis at week 54. The European League Against 
Rheumatism response criteria and disease activity were measured by 
the disease activity score in 28 joints (DAS28)–C-reactive protein (CRP) 
using the last observation carried forward method. Disease activity was 
deﬁ  ned as high disease activity, DAS28–CRP greater than 4.1; moderate 
disease activity, 2.7 or greater to 4.1 or less; low disease activity, 2.3 
or greater to less than 2.7; and DAS28–CRP remission, less than 2.3. 
*p<0.05 versus the 3 mg/kg groups.       
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 Figure  2        Correlation of plasma tumour necrosis factor alpha (TNF) levels before inﬂ  iximab therapy (baseline-TNF) with (A) the European League 
Against Rheumatism (EULAR) response, (B) the disease activity score in 28 joints (DAS28) and (C) American College of Rheumatology (ACR) core 
set at week 54. Patients were divided into three patients groups by the baseline-TNF level as follows: TNF-low patients, less than 0.55 pg/ml; TNF-int 
patients, 0.55 pg/ml or greater to less than 1.65 pg/ml; and TNF-high patients, 1.65 pg/ml or greater. EULAR response criteria for disease activity were 
measured by DAS28–C-reactive protein (CRP). Disease activity was deﬁ  ned as high disease activity (HDA), DAS28–CRP greater than 4.1; moderate 
disease activity (MDA), 2.7 or greater to 4.1 or less; low disease activity (LDA), 2.3 or greater to less than 2.7; and DAS28–CRP remission, less than 
2.3. All clinical responses were evaluated by using the last observation carried forward method. *Kendall rank correlation coefﬁ   cient.    
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CRP was reported to be associated with the serum inﬂ  iximab 
level,    47    but no consensus has been obtained about the correla-
tion between baseline CRP and clinical response.    36        48    We inves-
tigated the inﬂ  uence of baseline CRP on the clinical response as 
an index of EULAR response as done by baseline-TNF. However, 
we could ﬁ  nd no clear relationship between them (supplemen-
tary ﬁ  gure 3A,B, available online only). Given that TNF is one 
of the key cytokines that induce CRP in various inﬂ  ammatory 
diseases such as RA, it is reasonable that baseline-TNF, rather 
than CRP, would be a good predictor of clinical response to the 
TNF inhibitor, inﬂ  iximab. 
  Many contradictory reports have been published regarding 
the effectiveness of dose escalation with inﬂ  iximab.    18       –       20        26       –       32    
The reason why no consensus has been reached is that dose 
escalation is signiﬁ  cant only in TNF-high patients, so the results 
of reports have been inﬂ  uenced by the number of patients with 
high baseline-TNF included in those studies. In the RISING 
study, TNF-high patients accounted for approximately 13% of 
the total. 
  This study may provide insight into our understanding of the 
relationship between the concentration of circulating cytokines 
and the dose of antibodies against the cytokines in the treatment 
of RA. As mentioned by van Vollenhoven,    26    an attempt to apply 
results obtained under highly controlled circumstances at the 
group level to the unique individual is necessary. These results 
may be useful for establishing treatment strategies, such as the 
appropriate dose of inﬂ  iximab in accordance with baseline-TNF 
in patients with RA, not only in daily clinical practice but also in 
relation to the economics of health care.     
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